Product Images Fulvestrant
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 16 images provide visual information about the product associated with Fulvestrant NDC 71731-6121 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This is a table that shows the Progression Free Survival for two doses of Fulvestrant (250mg and 500mg) over the course of 45 months. The information shows the number of patients at risk for each time point.*
This appears to be a graph displaying the "Progression-Free Survival Probability" for two different treatments: "fulvestrant+palbociclib" and "fulvestrant+placebo". The X-axis shows the time in months and the Y-axis displays the survival probability in percentages. The number of patients at risk is indicated but it is not clear what the exact numbers represent without context.*
The text describes survival probability percentages for two drug combinations (fulvestrant+palbociclib and fulvestrant+placebo) for the different stages of time (in months). The description is accompanied by the number of patients at risk for each drug combination. Therefore, this text is useful for examining clinical trial results for these two drug combinations.*
This is a description of a medication called Fulvestrant Injection. It comes in a package that includes two single-dose pre-filled syringes with a 250mg dosage each. This medication is administered through an intramuscular injection. The text is partially garbled and has some errors, but the general information about the medication is discernible.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.